118764-13-9

Usage

Uses

Used in Pharmaceutical Industry:
C-(2H-TETRAZOL-5-YL)-METHYLAMINE HYDROCHLORIDE is used as a synthetic intermediate for the development of various pharmaceuticals, including antihypertensive drugs and other biologically active compounds. Its tetrazole ring provides unique properties that can be leveraged in drug design to improve efficacy and pharmacokinetics.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, C-(2H-TETRAZOL-5-YL)-METHYLAMINE HYDROCHLORIDE is utilized as a key component in the synthesis of new drugs and biologically active molecules. Its presence in these compounds can contribute to their biological activity, making it a valuable tool for researchers in drug discovery and development.
Used in Research and Development:
C-(2H-TETRAZOL-5-YL)-METHYLAMINE HYDROCHLORIDE is employed in research and development settings, particularly within the pharmaceutical industry, to explore its potential applications in the synthesis of novel drugs and other therapeutic agents. Its hydrochloride salt form facilitates its use in laboratory processes, making it a preferred choice for researchers working on drug synthesis and optimization.

Upstream product

• 119851-20-6 (6RS,13RS)-5H,12H-6,13-Methano-7H,14H-ditetrazolo<1,5-c:1',5'-h><1,3,6,8>tetrazecin 
• 1340483-79-5 benzhydryl-[1-(1,1,3,3-tetramethylbutyl)-1H-tetrazol-5-ylmethyl]amine 
• 112273-70-8 N-((1H-tetrazol-5-yl)methyl)benzamide 

Downstream Products

• 31602-63-8 (1H-tetrazol-5-yl)methanamine 
• 1427588-75-7 C₂₁H₂₁ClN₈O*C₂HF₃O₂ 
• 1220897-94-8 C₂₈H₃₁Cl₂N₇O₂ 

Relevant academic research and scientific papers

Cleavable β-Cyanoethyl Isocyanide in the Ugi Tetrazole Reaction

β-Cyanoethyl isocyanide is introduced as a cleavable isocyanide in the Ugi tetrazole reaction. Eleven examples are described that exhibit a broad scope and are obtained in good overall yields. The obtained 1H-tetrazole scaffold is an important bioisostere for carboxylic acids, and the method described here is a valuable alternative route to known procedures.

Indazole derivative, composition and uses thereof

The present invention discloses an indazole derivative represented by a formula (I) and used for treating type 2 diabetes mellitus or a pharmaceutically acceptable salt, a solvate, a metabolite, a polymorph, a tautomer or a prodrug thereof. The present invention further discloses a pharmaceutical composition containing the substance, applications of the composition in preparation of drugs, and a method for treating type II diabetes mellitus. The formula (I) is defined in the specification.

Design, Synthesis, and in Vitro and in Vivo Evaluation of an 18F-Labeled Sphingosine 1-Phosphate Receptor 1 (S1P1) PET Tracer

Sphingosine 1-phosphate receptor 1 (S1P1) plays a pivotal signaling role in inflammatory response; because S1P1 modulation has been identified as a therapeutic target for various diseases, a PET tracer for S1P1 would be a useful tool. Fourteen fluorine-containing analogues of S1P ligands were synthesized and their in vitro binding potency measured; four had high potency and selectivity for S1P1 (S1P1 IC50 100-fold selectivity for S1P1 over S1P2 and S1P3). The most potent ligand, 28c (IC50 = 2.63 nM for S1P1) was 18F-labeled and evaluated in a mouse model of LPS-induced acute liver injury to determine its S1P1-binding specificity. The results from biodistribution, autoradiography, and microPET imaging showed higher [18F]28c accumulation in the liver of LPS-treated mice than controls. Increased expression of S1P1 in the LPS model was confirmed by immunohistochemical analysis (IHC). These data suggest that [18F]28c is a S1P1 PET tracer with high potential for imaging S1P1 in vivo.

α-Amino Acid-Isosteric α-Amino Tetrazoles

The synthesis of all 20 common natural proteinogenic and 4 otherα-amino acid-isosteric α-amino tetrazoles has been accomplished, whereby the carboxyl group is replaced by the isosteric 5-tetrazolyl group. The short process involves the use of the key Ugi tetrazole reaction followed by deprotection chemistries. The tetrazole group is bioisosteric to the carboxylic acid and is widely used in medicinal chemistry and drug design. Surprisingly, several of the common α-amino acid-isosteric α-amino tetrazoles are unknown up to now. Therefore a rapid synthetic access to this compound class and non-natural derivatives is of high interest to advance the field.

Aminomethyltetrazoles as potential inhibitors of the c-aminobutyric acid transporters mGAT1-mGAT4: Synthesis and biological evaluation

1,5-Disubstituted and 5-monosubstituted aminomethyltetrazole derivatives derived from glycine were synthesized employing a TMSN3-modified variant of the Ugi reaction as a key step. All compounds were evaluated regarding their inhibitory potency and subtype selectivity at the four murine GABA transporter subtypes mGAT1-mGAT4. Though none of the 5-monosubstituted tetrazoles turned out to inhibit [3H]GABA uptake to a significant extent, the 1,5-disubstituted tetrazole derivatives displayed a distinct activity, especially at the GABA transport proteins mGAT2-mGAT4. Thus, a reasonable potent and selective inhibitor of mGAT3 was found. Additionally, two more compounds were identified as potent inhibitors of mGAT2. This is especially relevant, as up to date only few potent inhibitors of mGAT2 that do not affect mGAT1 are known.

SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administeri

NOVEL COMPOUNDS

Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis. In Formula (I) R1, R2, R3, R4, R5, R6, X and Y are as d

A Methanoditetrazolo-tetrazecine from 5-(Chloromethyl)tetrazole and Hexamethylenetetramine

In contrast to N-substituted 5-(chloromethyl)tetrazoles (1; R = alkyl, aryl), the parent compound 1 (R = H) reacts with hexamethylenetetramine to give the methanoditetrazolo-tetrazecine 4, a rather unusual system.This compound which is also produced on reaction of 7 with formaldehyde occurs in the (6RS,13RS) form.